Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Royalty Pharma $1.5 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Medtronic €3 billion notes offering
The notes are due 2029, 2036, 2043 and 2053
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2029, 2034 and 2054
Merck €3.4 billion notes offering
The investment-grade notes offering consists of four tranches
Perspective Therapeutics $80 million offering
The stock is listed on the NYSE American
Asahi Kasei $1.1 billion offer to acquire Calliditas Therapeutics
We are advising Lazard as financial adviser to Calliditas on the transaction
Nordson $800 million acquisition of Atrion
We are advising Nordson on the acquisition
AC Immune exclusive option and license agreement with Takeda Pharmaceuticals
We advised AC Immune on the transaction
RxSight $115 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market